Terminated/Withdrawn
Sponsor ID
20080451
AMG 761 in Adults with Asthma
Study Details
The purpose of this study is to determine that no significant safety issues will be identified following a single dose of AMG 761 in asthma subjects that would preclude further development of AMG 761.
Protocol Summary
Primary Outcome Measures
The number of treatment emergent adverse events per subject including clinically significant changes in vital signs, physical examinations, laboratory safety tests and ECGs.
Timeframe: 16 weeks
The number of subjects with anti-AMG 761 antibodies after a single dose of AMG 761.
Timeframe: 16 weeks
Secondary Outcome Measures
The maximum observed concentration, time to maximum concentration and the area under the serum concentration-time curve after a single dose of AMG 761.
Timeframe: 16 weeks
The circulating CD4+ CCR4+ T cell count.
Timeframe: 16 weeks
Study Documents
Study Synopsis
Available Language(s): English
Locations
Location
Research Site
Miami, FL, United States, 33143
Status
Recruiting
Location
Research Site
Denver, CO, United States, 80206
Status
Recruiting